IPO - NEUROONE MEDICAL TECHNOLOGIES Corp

Form Type: 424B5

Filing Date: 2025-04-04

Corporate Action: Ipo

Type: New

Accession Number: 000121390025028999

Filing Summary: NeuroOne Medical Technologies Corporation is offering 16,000,000 shares of its common stock at a public offering price of $0.50 per share. The total anticipated proceeds from the offering are approximately $8,000,000 before underwriting discounts and expenses, with net proceeds estimated to be around $7.1 million. The shares are listed on the Nasdaq Capital Market under the symbol 'NMTC'. There is a high degree of investment risk associated with this offering, and potential investors are advised to read the prospectus supplement for comprehensive details, including risk factors and use of proceeds. Certain officers of the company have indicated interest in purchasing $150,000 worth of shares at the same terms as offered to the public, although this represents only an indication of interest without binding commitments. The underwriters have an option to purchase an additional 2,400,000 shares of common stock depending on market demands. Plans for using the proceeds focus on general working capital purposes. Additionally, the company mentions its FDA clearances for several medical devices, including those for treatment procedures for neurological conditions. The offering is subject to customary closing conditions, with the expected delivery date for shares being April 7, 2025.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-04-03

Corporate Action: Ipo

Type: New

Accession Number: 000121390025028612

Filing Summary: NeuroOne Medical Technologies Corporation is offering shares of its common stock, par value $0.001 per share, as part of a preliminary prospectus supplement filed pursuant to Rule 424(b)(5). This document is associated with an effective registration statement (No. 333-279871) that has been declared effective by the SEC on August 16, 2024. The public offering price for the shares is yet to be determined, with the last reported sale price of the company's stock at $0.86 per share as of April 2, 2025. The aggregate market value of outstanding common stock held by non-affiliates is approximately $36.6 million based on the number of shares outstanding. The company has not sold any securities pursuant to General Instruction I.B.6 of Form S-3 within the last 12 months, allowing for an estimated offering price of up to $9.7 million. The shares are expected to be delivered around a date to be determined in 2025, pending the fulfillment of customary closing conditions. This offering is part of the company's strategy to raise funds for working capital purposes, which is critical for their ongoing development of medical technology focused on brain-related conditions, including diagnostic and stimulation technologies, as well as ablation systems and drug delivery capabilities. The significant risks associated with this investment include potential dilution from future sales of shares, market volatility, and risks inherent in the medical technology sector. Additionally, management retains broad discretion in the use of proceeds from this offering, which may not produce immediate financial benefits.

Document Link: View Document